Drug Trial Radar · NCT02970318
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
310
Actual
Start
Feb 2, 2017
Primary completion
Sep 3, 2021
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Acerta Pharma BVAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
Conditions
- Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib (ACP-196)Drug
Acalabrutinib monotherapy
RituximabDrug
Rituximab in combination with idelalisib or bendamustine
IdelalisibDrug
Idelalisib in combination with rituximab
BendamustineDrug
Bendamustine in combination with rituximab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) Per Independent Review Committee (IRC) AssessmentTime frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Locations
157 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Oxnard, California
Research Site
Athens, Georgia
Research Site
Joliet, Illinois
Research Site
Cedar Rapids, Iowa
Research Site
Mount Sterling, Kentucky
Research Site
Saint Cloud, Minnesota
Research Site
Lincoln, Nebraska
Research Site
Brick, New Jersey
Research Site
Nyack, New York
Research Site
Canton, Ohio
Research Site
Fort Sam Houston, Texas
Research Site
Round Rock, Texas
Research Site
Adelaide, Australia
Research Site
Box Hill, Australia
Research Site
Frankston, Australia
Research Site
Geelong, Australia
Research Site
Gosford, Australia
Research Site
Hobart, Australia
Research Site
Kogarah, Australia
Research Site
Murdoch, Australia
Research Site
Nedlands, Australia
Research Site
South Brisbane, Australia
Research Site
Woodville, Australia
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Wels, Austria
Research Site
Antwerp, Belgium
Research Site
Ghent, Belgium
Research Site
Roeselare, Belgium
Research Site
Yvoir, Belgium
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Vratsa, Bulgaria
Research Site
Calgary, Canada
Research Site
Montreal, Canada
Research Site
Ottawa, Canada
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.